Side-by-side comparison of AI visibility scores, market position, and capabilities
Mumbai smartphone-based diagnostic platform with color-change test cards for UTI, diabetes, and kidney tests for 4K+ doctors; YC S21 $2.48M Omidyar Network-backed with Cipla/Sun Pharma/AstraZeneca partnerships for India at-home diagnostics.
Neodocs is a Mumbai, India-based healthtech company — backed by Y Combinator (S21) with $2.48 million raised including a $2 million seed round in February 2024 led by Omidyar Network India with YC, 9Unicorns, Gemba Capital, Titan Capital, and 100Unicorns — providing instant at-home diagnostic test kits with proprietary biochemistry test cards that deliver visual color-change results for conditions including urinary tract infections, diabetes monitoring (HbA1c and glucose), kidney function (creatinine, protein), and general wellness panels without requiring any additional hardware beyond a smartphone camera. Founded in 2020, Neodocs has sold 200,000+ test cards used by 4,000+ doctors across India and has partnerships with major pharmaceutical companies including Cipla, Sun Pharma, and AstraZeneca for co-branded diagnostic test distribution.
Dominant browser-based collaborative UI design platform at ~$600M ARR and $12.5B valuation; Adobe's $20B acquisition blocked by regulators in 2023, Figma remains independent competing with Sketch and Adobe.
Figma is a San Francisco-based collaborative web-based product design platform that has become the dominant tool for UI/UX designers and product teams — enabling real-time multi-user collaboration on interface design, prototyping, and design system management directly in the browser without installing desktop software. Founded in 2012 by Dylan Field and Evan Wallace and backed by Sequoia, Greylock, and Andreessen Horowitz with over $330 million raised, Figma generated approximately $600 million in ARR in 2023, serving 4 million+ designers and product teams at companies including Microsoft, Airbnb, Twitter, and Uber. Adobe announced a $20 billion acquisition offer in 2022, which was blocked by regulators in 2023 — Figma remains independent.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.